ACP 001

Drug Profile

ACP 001

Alternative Names: ACP-001; TransCon growth hormone; TransCon PEG growth hormone; TransCon PEG hGH; TransCon PEG somatropin

Latest Information Update: 12 Aug 2016

Price : $50

At a glance

  • Originator Ascendis Pharma
  • Class Hormonal replacements; Polyethylene glycols
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Somatotropin deficiency

Most Recent Events

  • 11 Aug 2016 Phase-III clinical trials in Somatotropin deficiency (In children, Treatment-naive) in USA (SC) (NCT02781727)
  • 30 Jul 2015 Immunogenicity data from a phase II trial in Somatotrophin deficiency (Treatment-naive, In children) released by Ascendis
  • 30 Jul 2015 Ascendis Pharma completes a phase II trial in Somatotrophin deficiency (Treatment-naive, In children) in Germany, Greece, Hungary, Slovenia, Bulgaria, Czech Republic, France, Poland, Romania, Belarus, Turkey, Russia, Ukraine and Egypt , NCT01947907) before July 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top